SPRY4 Intronic Transcript 1 Promotes Epithelial–Mesenchymal Transition Through Association with Snail1 in Osteosarcoma

Ru, Neng; Liang, Jie; Zhang, Fan; Wu, Weifei; Wang, Feifan; Liu, Xinzong; Du, Yuan-li

doi:10.1089/dna.2016.3226

Cited by 15 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides these two mechanisms, others have also been identified, including the direct interaction of lncRNAs with proteins involved in EMT [243,250,264] and regulation of mRNA translation [154]. For many of the lncRNAs identified so far, exactly how they regulate EMT is unknown (Table 1).…”

Section: Discussionmentioning

confidence: 99%

“…Other examples of this complexity include SPRY4-IT1, which is derived from an intron of SPRY4, is upregulated in many cancers and has been shown to induce EMT in colorectal cancer, gliomas, HCC, oesophageal squamous cell carcinoma and osteosarcoma [264,266,267,380,381,382,383,384]. In bladder cancer, SPRY4-IT1 is upregulated [385] and induces metastasis whereby it acts as a ceRNA for miR-101-3p, resulting in up-regulation of EZH2 [265].…”

Section: Lncrnas and Emt: The Main Playersmentioning

confidence: 99%

See 1 more Smart Citation

Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells

Heery

Finn

Cuffe

et al. 2017

Cancers

156

140

View full text Add to dashboard Cite

Epithelial mesenchymal transition (EMT), the adoption by epithelial cells of a mesenchymal-like phenotype, is a process co-opted by carcinoma cells in order to initiate invasion and metastasis. In addition, it is becoming clear that is instrumental to both the development of drug resistance by tumour cells and in the generation and maintenance of cancer stem cells. EMT is thus a pivotal process during tumour progression and poses a major barrier to the successful treatment of cancer. Non-coding RNAs (ncRNA) often utilize epigenetic programs to regulate both gene expression and chromatin structure. One type of ncRNA, called long non-coding RNAs (lncRNAs), has become increasingly recognized as being both highly dysregulated in cancer and to play a variety of different roles in tumourigenesis. Indeed, over the last few years, lncRNAs have rapidly emerged as key regulators of EMT in cancer. In this review, we discuss the lncRNAs that have been associated with the EMT process in cancer and the variety of molecular mechanisms and signalling pathways through which they regulate EMT, and finally discuss how these EMT-regulating lncRNAs impact on both anti-cancer drug resistance and the cancer stem cell phenotype.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Lncrnas and Emt: The Main Playersmentioning

confidence: 99%

Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells

Heery

Finn

Cuffe

et al. 2017

Cancers

156

140

View full text Add to dashboard Cite

show abstract

“…In addition, SPRY4-IT1 also demonstrated the oncogenic role via targeting zinc finger protein 703 in breast cancer and ESCC [15, 20]. In the osteosarcoma, SPRY4-IT1 can promote epithelial mesenchymal transition via interaction with Snail [21]. More importantly, the knock-down of SPRY4-IT1 inhibited cell growth and cell differentiation, also induced apoptosis in melanoma [10].…”

Section: Discussionmentioning

confidence: 99%

Prognostic role of the long non-coding RNA, SPRY4 Intronic Transcript 1, in patients with cancer: a meta-analysis

et al. 2017

View full text Add to dashboard Cite

Recent studies have emphasized the important role of long non-coding RNAs (lncRNAs) in cancer development. The present study performed a meta-analysis to investigate whether lncRNA, SPRY4 Intronic Transcript 1(SPRY4-IT1) can be served as a potential biomarker for prognosis in human cancers. The eligible studies were collected by searching multiple online databases (Pubmed, EMBASE, CNKI, Web of Science and Google Scholar) and meta-analysis was performed to explore the association between the expression levels of SPRY4-IT1 and overall survival (OS), disease-free survival (DFS) and clinicopathological parameters. A total of 1329 patients from 13 studies were included for meta-analysis. The meta-analysis results showed that high expression level of SPRY4-IT1 was significantly associated with shorter OS in cancer patients (HR = 3.20, 95% CI: 2.59-3.90, P<0.001) except in the patients with non-small cell lung cancer (NSCLC). Increased SPRY4-IT1 expression level was correlated with shorter DFS in patients with gastric cancer and ovarian cancer. SPRY4-IT1 expression level was not correlated with the clinicopathological parameters including age (P = 0.37), gender (P = 0.87), tumor size (P = 0.47) and invasion depth (P = 0.52), and increased SPRY4-IT1 expression level was significantly associated with distant metastasis (odds ratio (OR) = 1.96, 95% CI: 1.24-3.08, P = 0.004), lymph node metastasis (OR = 3.96, 95% CI: 1.48-5.54, P<0.001), advanced tumor/node/metastasis stage (OR = 3.72, 95% CI = 2.91-4.76, P<0.001) and poor tumor differentiation (OR = 1.86, 95% CI = 1.35-2.58, P<0.001) in cancer patients except in patients with NSCLC. In summary, the meta-analysis results suggested that increased expression level of SPRY4-IT1 was positively associated with unfavorable prognosis and advanced features of cancers in cancer patients but not in patients with NSCLC.

show abstract

“…We then determined whether SPRY4-IT1 expression influences tumor-like characteristics such as proliferation and apoptosis [24]. Our results showed that knockdown of SPRY4-IT1 by siRNA in LoVo and SW480 cells was shown to significantly inhibit CRC cell growth and colony formation, and increase cell apoptosis, whereas the ectopic expression of SPRY4-IT1 significantly enhances cell proliferation in RKO cell lines.…”

Section: Discussionmentioning

confidence: 99%

Long non-coding RNA SPRY4-IT1 pormotes colorectal cancer metastasis by regulate epithelial-mesenchymal transition

et al. 2016

View full text Add to dashboard Cite

Colorectal cancer (CRC) remains one of the most common cancers worldwide. Increasing evidence indicates that SPRY4 intronic transcript 1 (SPRY4-IT1) regulate cell growth, differentiation, apoptosis, and cancer progression. However, the expression and function of SPRY4-IT1 in the progression of CRC remains largely unknown. Here, we reported that SPRY4-IT1 was upregulated in CRC. Increased SPRY4-IT1 expression in CRC was associated with larger tumor size and higher clinical stage. In vitro experiments revealed that SPRY4-IT1 knockdown significantly inhibited CRC cell proliferation by causing G1 arrest and promoting apoptosis, whereas SPRY4-IT1 overexpression promoted cell proliferation. Further functional assays indicated that SPRY4-IT1 overexpression significantly promoted cell migration and invasion by regulate the epithelial-mesenchymal transition (EMT). Taken together, our study demonstrates that SPRY4-IT1 could act as a functional oncogene in CRC, as well as a potential therapeutic target to inhibit CRC metastasis.

show abstract

SPRY4 Intronic Transcript 1 Promotes Epithelial–Mesenchymal Transition Through Association with Snail1 in Osteosarcoma

Cited by 15 publications

References 29 publications

Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells

Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells

Prognostic role of the long non-coding RNA, SPRY4 Intronic Transcript 1, in patients with cancer: a meta-analysis

Long non-coding RNA SPRY4-IT1 pormotes colorectal cancer metastasis by regulate epithelial-mesenchymal transition

Contact Info

Product

Resources

About